Relay Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Relay Therapeutics, Inc. (RLAY) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 108.64 million shares for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-08-04
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-06-30 was 108.64M shares, a 18.17% increase year-over-year.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 108.29M shares, a 20.06% increase year-over-year.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 102.75M shares, a 13.94% increase year-over-year.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 92.69M shares, a 30.10% increase year-over-year.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 95.14M shares, a 123.22% increase from fiscal 2020.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 42.62M shares, a 1135.17% increase from fiscal 2019.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 3.45M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | 108.64M shares 10-Q · filed 2022-08-04 | 108.47M shares 10-Q · filed 2022-08-04 | 106.56M shares derived: average of 3 quarters · filed 2022-08-04 | 103.09M shares derived: average of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 108.29M shares 10-Q · filed 2022-05-05 | 105.52M shares derived: average of 2 quarters · filed 2022-05-05 | 101.24M shares derived: average of 3 quarters · filed 2022-05-05 | 98.92M shares derived: average of 4 quarters · filed 2022-08-04 |
| 2021-12-31 | 102.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 97.72M shares derived: average of 2 quarters · filed 2022-02-24 | 95.79M shares derived: average of 3 quarters · filed 2022-08-04 | 95.14M shares 10-K · filed 2022-02-24 |
| 2021-09-30 | 92.69M shares 10-Q · filed 2021-11-10 | 92.32M shares derived: average of 2 quarters · filed 2022-08-04 | 92.60M shares 10-Q · filed 2021-11-10 | 91.25M shares derived: average of 4 quarters · filed 2022-08-04 |
| 2021-06-30 | 91.94M shares 10-Q · filed 2022-08-04 | 91.19M shares 10-Q · filed 2022-08-04 | 90.77M shares derived: average of 3 quarters · filed 2022-08-04 | 85.89M shares derived: average of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | 90.20M shares 10-Q · filed 2022-05-05 | 90.19M shares derived: average of 2 quarters · filed 2022-05-05 | 83.87M shares derived: average of 3 quarters · filed 2022-05-05 | 64.01M shares derived: average of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | 90.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 80.71M shares derived: average of 2 quarters · filed 2022-02-24 | 55.28M shares derived: average of 3 quarters · filed 2022-02-24 | 42.62M shares 10-K · filed 2022-02-24 |
| 2020-09-30 | 71.25M shares 10-Q · filed 2021-11-10 | 37.83M shares derived: average of 2 quarters · filed 2021-11-10 | 26.77M shares 10-Q · filed 2021-11-10 | 20.91M shares derived: average of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | 4.41M shares 10-Q · filed 2021-08-12 | 4.28M shares 10-Q · filed 2021-08-12 | 4.13M shares derived: average of 3 quarters · filed 2022-02-24 | 3.99M shares derived: average of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | 4.15M shares 10-Q · filed 2021-05-13 | 3.99M shares derived: average of 2 quarters · filed 2022-02-24 | 3.85M shares derived: average of 3 quarters · filed 2022-02-24 | 3.72M shares derived: average of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | 3.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 3.69M shares derived: average of 2 quarters · filed 2022-02-24 | 3.57M shares derived: average of 3 quarters · filed 2022-02-24 | 3.45M shares 10-K · filed 2022-02-24 |
| 2019-09-30 | 3.56M shares 10-Q · filed 2020-11-12 | 3.44M shares derived: average of 2 quarters · filed 2020-11-12 | 3.32M shares 10-Q · filed 2020-11-12 | |
| 2019-06-30 | 3.32M shares 10-Q · filed 2020-08-27 | 3.21M shares 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |